Citi initiated coverage of Novo Nordisk (NVO) with a Neutral rating and DKK 400 price target The firm views the stock’s valuation as appropriate at current share levels.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’
- Moderately bullish activity in Novo Nordisk with shares up 0.14%
- Novo Nordisk’s Real‑World Semaglutide Study Hits Completion: What Investors Should Watch
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Novo Nordisk Stock (NVO) Gains on Obesity Pill Demand as Goldman Flags Earnings Upside